Purified anti-human HLA-A,B,C Antibody

Pricing & Availability
Clone
W6/32 (See other available formats)
Regulatory Status
RUO
Other Names
Major Histocompatibility Class I, MHC class I
Isotype
Mouse IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
a-W632_Purified_072607
Human peripheral blood lymphocytes were stained with purified anti-HLA-A,B,C (clone W6/32, filled histogram) or purified mouse IgG2a, κ isotype control (open histogram), followed by goat-anti-mouse IgG FITC.
  • a-W632_Purified_072607
    Human peripheral blood lymphocytes were stained with purified anti-HLA-A,B,C (clone W6/32, filled histogram) or purified mouse IgG2a, κ isotype control (open histogram), followed by goat-anti-mouse IgG FITC.
  • b-632_012105
    HEK293 cells were transfected with RelA or empty vector and 24hrs later cell extracts harvested using a 1% CHAPS lysis buffer. Extracts were resolved by non-denaturing, non-reducing electrophoresis, transferred to nitrocellulose, and probed with a 1:500 dilution purified W6/32 . Proteins were visualized using a goat anti-mouse secondary antibody conjugated to HRP and a chemiluminescence detection system. These data document that MHC class I was upregulated in cells constitutively expressing RelA. (Data was provided by Dr. Ezra Burstein, University of Michigan Medical School, Ann Arbor, MI).
Compare all formats
Cat # Size Price Quantity Check Availability Save
311402 100 µg $89
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

MHC class I antigens associated with β2-microglobulin are expressed by all human nucleated cells. MHC class I molecules are involved in presentation of antigens to CD8+ T cells. They play an important role in cell-mediated immune responses and tumor surveillance.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Human, Cynomolgus, Rhesus
Reported Reactivity
African Green, Baboon, Cat, Cow, Chimpanzee
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
Activ, Block, IHC-F, IP, WB - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 2.0 µg per 106 cells in 100 µl volume or 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Clone W6/32 recognizes residues in the N terminus of the human ß2-microglobulin molecule21.

Additional reported applications (for the relevant formats) include: immunoprecipitaton2, Western blotting (non-reducing)3, immunohistochemical staining of acetone-fixed frozen tissue sections4,5, blocking6,7, inhibition of NK cell-mediated lysis10, and activation8,9. Clone W6/32 has been reported not to be suitable for immunohistochemistry on paraffin sections17. The LEAF™ purified antibody (Endotoxin < 0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays. For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 311428) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Darrow TL, et al. 1989. J. Immunol. 142:3329.
  2. Stern P, et al. 1987. J. Immunol. 138:1088.
  3. Tran TM, et al. 2001. Immunogenetics 53:440.
  4. Barbatis C, et al. 1981. Gut 22:985.
  5. Ayyoub M, et al. 2004. Cancer Immunity 4:7.
  6. DeFelice M, et al. 1990. Cell. Immunol. 126:420.
  7. Fayen J, et al. 1998. Int. Immunol. 10:1347.
  8. Turco MC, et al. 1988. J. Immunol. 141:2275.
  9. Geppert TD, et al. 1989. J. Immunol. 142:3763.
  10. Wooden SL, et al. 2005. J. Immunol. 175:1383.
  11. Nagano M, et al. 2007. Blood 110:151.
  12. McLoughlin RM,et al.2008. J. Immunol. 181:1323. PubMed
  13. Takahara M, et al.2008. J. Leukoc. Biol. 83:742. PubMed
  14. Lunemann A, et al.2008. J. Immunol. 181:6170. PubMed
  15. Laing BJ, et al. 2010. J. Thorac Cardiovasc Surg. 139:1402. PubMed
  16. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  17. Vambutas A, et al. 2000. Clin. Diagn. Lab. Immun. 7:79.
  18. Coppieters KT, et al. 2012. J. Exp. Med. 209:51. (epitope)
  19. Crivello P, et al. 2013. Hum Immunol. 22:100. PubMed
  20. Jung Y, et al. 2015. Mol Cancer Res. 13:197. PubMed
  21. Shields MJ. Ribaudo RK. 1998. Tissue Antigens. 51(5):567-70. (epitope)
Product Citations
  1. Fu J et al. 2019. Cell stem cell. 24(2):227-239 . PubMed
  2. Chen WT, et al. 2018. J Invest Dermatol. 138:1546. PubMed
  3. Zhu Z, et al. 2022. Front Oncol. 12:814312. PubMed
  4. Gallen C, et al. 2022. Vaccines (Basel). 10:. PubMed
  5. Tsuchiya N, et al. 2018. Oncoimmunology. 7:e1377872. PubMed
  6. Abdul–Salam VB, et al. 2019. Circ Res. 124:52:00. PubMed
  7. Jimenez-Duran G, et al. 2022. Front Immunol. 13:918551. PubMed
  8. Chou JM, et al. 2022. Front Microbiol. 13:883597. PubMed
  9. Nguyen R, et al. 2021. Cancer Immunol Immunother. 70:721. PubMed
  10. Andersen R, et al. 2018. Cancer Immunol Res. 0.404166667. PubMed
  11. Laing B, et al. 2010. J Thorac Cardiovasc Surg. 139:1402. PubMed
  12. Hsiue EH, et al. 2021. Science. 371:. PubMed
  13. Rennier K, et al. 2020. Clin Cancer Res. 26:5019. PubMed
  14. Wroblewska A et al. 2018. Cell. 175(4):1141-1155 . PubMed
  15. Garrido C, et al. 2018. JCI Insight. 3:e120121. PubMed
  16. Willimsky G, et al. 2021. Elife. 10:. PubMed
  17. Takeuchi M, et al. 2010. J Mol Cell Biol. 0.179861111. PubMed
  18. Mirandola L, et al. 2017. Oncotarget. 8:74378. PubMed
  19. Sharma M, et al. 2020. Front Immunol. 11:1136. PubMed
  20. Moquin-Beaudry G, et al. 2022. Cell Rep Methods. 2:100153. PubMed
  21. Parker R, et al. 2020. bioRxiv. . PubMed
  22. A A, et al. 2016. Biotechnol Bioeng. 112: 2214-27. PubMed
  23. Fitzgerald W, et al. 2018. Am J Reprod Immunol. 80:e12860. PubMed
  24. Jung Y, et al. 2015. Mol Cancer Res. 13:197. PubMed
  25. Martin JC, et al. 2020. Cell. 178(6):1493-1508.e20.. PubMed
  26. Gañán-Gómez I, et al. 2022. Nat Med. . PubMed
  27. Crivello P, et al. 2013. Hum Immunol. 22:100. PubMed
  28. Yumoto K, et al. 2016. Sci Rep. 6:36520. PubMed
  29. Ruiz Cuevas MV, et al. 2021. Cell Reports. 34(10):108815. PubMed
  30. Higashi S, et al. 2022. J Cell Sci. 135:. PubMed
  31. Eccles JD, et al. 2020. Cell Rep. 30:351. PubMed
  32. Tanaka Y, et al. 2020. Sci Rep. 10:17284. PubMed
  33. Liu Y, et al. 2017. Clin Cancer Res. 23(2):514-522. PubMed
  34. Blees A, et al. 2017. Nature.. 10.1038/nature24627. PubMed
  35. Han EX, et al. 2021. NPJ Regen Med. 6:40. PubMed
  36. Chen YL, et al. 2020. J Exp Med. 217:. PubMed
  37. Nöll A, et al. 2017. Proc Natl Acad Sci U S A. 114: E438 - E447. PubMed
  38. Makarkov AI, et al. 2019. NPJ Vaccines. 4:17. PubMed
  39. Mujib S, et al. 2017. JCI Insight. 2:e93687. PubMed
  40. Cohen MA, et al. 2020. Cell Stem Cell. 26(4):579-592. PubMed
  41. McLoughlin R, et al. 2008. J Immunol. 181:1323. PubMed
  42. Song S, et al. 2021. Front Immunol. 12:705140. PubMed
  43. Neuperger P, et al. 2021. Cancers (Basel). 14:. PubMed
  44. Pierini S, et al. 2020. JCI Insight. 5:00. PubMed
  45. Takahara M, et al. 2008. J Leukoc Biol. 83:742. PubMed
  46. Pettmann J, et al. 2021. eLife. 10:00. PubMed
  47. Dinh HQ, et al. 2020. Immunity. 53(2):319-334.e6. PubMed
  48. Chevrier S, et al. 2018. Cell Syst. 0.675. PubMed
  49. Carlsten M, et al. 2019. Oncoimmunology. 8:e1534664. PubMed
  50. Jasmer B, et al. 2017. Oncotarget. 8:108643. PubMed
  51. Chen HC, et al. 2017. Immunol Cell Biol. 95:620. PubMed
  52. Lavin Y et al. 2017. Cell. 169(4):750-765 . PubMed
  53. Nosaka K, et al. 2021. Anticancer Res. 41:4741. PubMed
RRID
AB_314871 (BioLegend Cat. No. 311402)

Antigen Details

Structure
Ig superfamily
Distribution

All nucleated cells

Function
Antigen presentation
Ligand/Receptor
CD3/TCR, CD8
Biology Area
Immunology, Innate Immunity
Molecular Family
MHC Antigens
Antigen References

1. Barclay AN, et al. Eds. 1993. The Leukocyte Antigen FactsBook. Academic Press Inc. San Diego.

Gene ID
3105 View all products for this Gene ID
UniProt
View information about HLA-A on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 3    Revision Date: 09/06/2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login/Register
Remember me
Forgot your password? Reset Password
Request an Account